CJC-1295 and Ipamorelin are peptides often combined in wellness settings for growth-hormone-pathway support. This page explains what they are and how clinician-supervised programs through ElliotMeds work. It is educational and not medical advice.

Last updated: July 2, 2026

What Is CJC-1295 / Ipamorelin?

This is a compounded blend of two peptides. CJC-1295 is a long-acting growth-hormone-releasing-hormone (GHRH) analog studied for stimulating the body's own growth-hormone (GH) and IGF-1 signaling. Ipamorelin is a selective GH secretagogue that acts at the ghrelin/GH-secretagogue receptor. This combination is not an FDA-approved therapy for general wellness, muscle growth, anti-aging, or recovery.

How It Works

CJC-1295 is intended to stimulate the GHRH pathway while ipamorelin acts through the GH-secretagogue receptor; the goal is to support the body's own pulsatile GH release rather than administering growth hormone directly. Research suggests these mechanisms in pharmacology studies, but robust human outcome evidence for wellness, muscle, and recovery claims is limited. It is not a guaranteed outcome.

What It’s Studied For

CJC-1295 has been studied in healthy adults for pharmacokinetic/pharmacodynamic effects on GH and IGF-1; ipamorelin has pharmacologic and preclinical data as a selective GH secretagogue. The combination has far less human outcome data than FDA-approved medications, and the FDA has identified peptide-characterization and safety concerns for CJC-1295 and ipamorelin-related substances. It is not FDA-approved for these uses.

What to Expect

Any use is framed only as provider-directed support, not a guaranteed result or timeline. Effects, if any, are individual and unverified for these purposes. This program promises no specific outcome.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Reported effects include injection-site reactions, headache, flushing, water retention, and numbness/tingling.
• There are possible effects on glucose metabolism and theoretical risks from chronically elevated IGF-1.
• Product purity and impurities are a concern with compounded or non-approved peptides, and the FDA has flagged CJC-1295 and ipamorelin acetate on characterization/safety grounds.
• No peptide is "safe" without qualification.

Who Is Not a Candidate

Personal history of cancer or active malignancy, uncontrolled diabetes, and pregnancy/breastfeeding warrant particular caution; a clinician also reviews IGF-1/GH concerns, glucose status, edema/fluid retention, sleep apnea, cardiovascular risk, and your full medication list, and may determine it is not appropriate.

How It Compares

Ipamorelin alone acts only at the GH-secretagogue receptor; adding CJC-1295 introduces a GHRH-analog component. Both differ from GH-axis peptides such as tesamorelin and sermorelin. None is presented as superior, and a clinician determines what, if anything, is appropriate.

Frequently Asked Questions

References

• Peer-reviewed pharmacology literature on CJC-1295 and ipamorelin (PubMed)
• FDA compounding-safety communications on peptide characterization